A phase I study to investigate the safety of TEG001 cell suspension for infusion in patients with relapsed/refractory Acute Myeloid Leukemia/high-risk Myelodysplastic Syndrome (IPSS-R score >4,5) relapsed/refractory or Multiple Myeloma
Recruiting
- Conditions
- blood cancerhaematological cancer1001884910027655
- Registration Number
- NL-OMON47707
- Lead Sponsor
- niversitair Medisch Centrum Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 18
Inclusion Criteria
- Age >= 18-years
- Relapsed/refractory Acute Myeloid Leukemia/ high-risk Myelodysplastic
Syndrome (IPSS-R >4.5) or relapsed/refractory Multiple Myeloma, for which no
remaining standard of care or approved treatment options are available
Exclusion Criteria
- In the investigators judgment, the subject is unlikely to complete all
protocol-required study visits or procedures
- Other concurrent malignancy requiring treatment
- Active endogenous retrovirus
- Active GVHD and/or systemic immune suppression for GVHD
- Uncontrolled infections
- Inadequate renal, hepatic, pulmonary and cardiac function
- Pregnant or lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method